Hemophilia and Non-Cancer Trials
Below is a list of our current Hemophilia and Non-Cancer Trials
Sidebar
25.0591: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia (Meza ITP)
Principal Investigator
Kamila Cisak, MD
Description
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously [SC]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active ingredients in it.The participants will be treated with mezagitamab for up to 6 months. During the study, participants will visit their study clinic several times.
FInd more information at ClinicalTrials.gov
08.0388 - Protocol for the Cancer Database and Specimen Repository (CDSR) at the Brown Cancer Center (Previous Lung Repository).
Principal Investigator
Rebecca Redman, M.D.
Description
The mission of the Cancer Database and Specimen Repository (CDSR) is to collect clinical information and samples of human specimens from cancer patients and from control patients for research, and to distribute specimens to researchers for the advancement of science.